FDA Will Increase Financial Disclosure Requirements For Employees
This article was originally published in The Pink Sheet Daily
Executive Summary
Move follows the decision to have center directors vet employees’ consulting arrangements. Agency-wide review of outside activity requests finds no further conflicts beyond a situation at CBER that was questioned by the House Energy & Commerce Committee.
You may also be interested in...
FDA Employees’ Outside Activities Will Receive Scrutiny By Center Directors
Activities had been approved at lower levels, but the interim policy – issued following questions about behavior of NIH scientists – escalates the oversight. All outside activities by FDA employees will be reviewed as part of the development of a final policy.
Pink Sheet Podcast: Relyvrio And Public Promises, Allergy Biomarker Adcomms, PMDA In The USA
Pink Sheet reporters and editor discuss the implications of Amylyx following through on its pledge to remove Relyvrio from the market after its trial failed, an FDA idea to bring potential biomarkers for promising allergy and asthma treatments to advisory committees, and Japan’s PMDA opening an office in Washington D.C.
Pink Sheet Podcast: Mifepristone And Misinformation At SCOTUS, Understanding US FDA’s ODAC
Pink Sheet reporters and editor discuss the upcoming US Supreme Court arguments on mifepristone access, the SCOTUS reaction to the fight against misinformation, and the FDA’s Oncologic Drugs Advisory Committee going against three negative product reviews.